Atlanta, GANCT07609719Now EnrollingIRB Ready

Multiple Sclerosis Clinical Trial in Atlanta, GA

Access cutting-edge multiple sclerosis treatment through this phase 4 clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Genentech, Inc.

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access multiple sclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple sclerosis treatment provided free

Apply for This Atlanta Location

Check if you qualify for this multiple sclerosis clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Multiple Sclerosis Study in Atlanta

The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).

Sponsor: Genentech, Inc.

Who Can Participate

Inclusion Criteria

Diagnosis of RMS or PPMS according to the revised McDonald 2017 criteria
Documented Expanded Disability Status Scale (EDSS) score of 0-6.5, inclusive, at screening (or within 6 months of screening)
Participants discontinuing aCD20 therapy for reasons including, but not limited to, physician/participant preference, access to commercial drug (e.g., insurance coverage issues), or other logistical reasons (such as geographical relocation, travel, etc.) are eligible for this study
Prior treatment with ofatumumab SC, ublituximab-xiiy IV, or ocrelizumab IV aCD20 therapy

Exclusion Criteria

Participants who have demonstrated suboptimal response to aCD20 therapy
Discontinuing aCD20 therapy because of any of the following treatment emergent adverse events (TEAEs): 1) Grade ≥3 severe infusion-related reaction (IRRs) or injection reactions (IRs); 2) Recurrent Grade ≥3 infections, or the need for ≥2 courses of antibiotics after starting aCD20 therapy, if the investigator believes infection is related to therapy
Participants with contraindication to Gd+ and participants who for any reason cannot tolerate MRI procedure
Known presence of active, recurrent, or chronic infection (e.g., human immunodeficiency virus \[HIV\], syphilis, human papillomavirus \[HPV\], tuberculosis \[TB\])
History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
Known presence of neurologic disorders that may interfere with the diagnosis of RMS or PPMS
Any concomitant disease that may require treatment with systemic corticosteroids (e.g., mineralocorticoids and glucocorticoids) or immunosuppressants during the study
Known allergy or hypersensitivity to ocrelizumab, rHuPH20, or excipients of the OCR SC formulation
Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
Treatment with any live-attenuated vaccine within 6 weeks prior to baseline
Treatment with any experimental procedures for RMS or PPMS (e.g., treatment for chronic cerebrospinal venous insufficiency)
Previous treatment with cladribine, atacicept, alemtuzumab or mitoxantrone
Positive hepatitis B virus (HBV) and hepatitis C virus (HCV) antibody test at screening Other protocol defined inclusion and exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT07609719) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Sclerosis Treatment Options in Atlanta, GA

If you're searching for multiple sclerosis treatment options in Atlanta, GA, this clinical trial (NCT07609719) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple sclerosis clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Atlanta, GA

See all multiple sclerosis clinical trials recruiting in Atlanta — not just this study.

Browse Multiple Sclerosis Trials in Atlanta →

Browse More Trials by Condition

Multiple Sclerosis TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA